Repare Therapeutics' shareholders have approved its acquisition by XenoTherapeutics, marking a significant step in advancing precision oncology research.

Overview of the Acquisition

Repare Therapeutics Inc. ("Repare" or the "Company"), a clinical-stage precision oncology firm, has announced that its shareholders have overwhelmingly approved the acquisition of all issued and outstanding common shares by XenoTherapeutics, Inc. and Xeno Acquisition Corp. (collectively, "Xeno"). This agreement, reached during a special shareholders' meeting, was approved with 99.76% of votes in favor from those present in person or represented by proxy.

The resolution was significant not only for the approval of the acquisition but also included advisory support for executive compensation related to the transaction and the potential voluntary liquidation of Repare in the event the arrangement is terminated. The final approval of this acquisition is pending a court hearing set for January 23, 2026, with completion expected shortly thereafter, assuming all customary conditions are met.

Industry Overview in the Target's Country

The biotechnology and pharmaceutical industries in Canada have increasingly gained global prominence, particularly in precision medicine. The emphasis on specialized treatments, such as those aimed at specific ge